Dublin, Ireland – February 4th, 2016 – Aalto Bio Reagents today announced the availability of its new Zika Virus monoclonal antibodies for diagnostic test manufacturers and researchers globally. The World Health Organisation (WHO) declared Zika Virus an international public health emergency on Monday, February 1st 2016. Zika Virus, a mosquito-borne flavivirus, is linked to severe birth defects such as microcephaly, in babies whose mothers have been exposed to the virus during pregnancy. Zika Virus is spreading rapidly through the Americas currently, with the outbreak being documented in 30 countries to date.
While there is no commercially available serology test for Zika Virus at present; Aalto Bio Reagents Ltd. is leading the field in supporting development of such assays through supply of its recombinant Zika Virus NS1 and Envelope proteins which were launched in November 2015. Following the overwhelming positive response to these products, Aalto Bio Reagents has developed the first mouse monoclonal antibodies to Zika NS1 protein and Envelope protein and is first to market in offering a unique raw material to fast track the development of Zika diagnostic tests, thus aiding faster diagnosis and better treatment.
Philip Noone, CEO of Alto Bio Reagents said “The Zika Virus outbreak is a major global concern, with two HSE confirmed cases of Zika Virus in Ireland as of yesterday. In light of this, it is becoming more apparent than ever the need for access to the most scientifically proven raw materials in outbreak situations like this, where fast diagnosis is required. At Aalto Bio Reagents we are continuously expanding our product portfolio to meet this need. This is cemented by the development and first-in- market availability on our Zika Virus antigens and monoclonal antibodies. We are proud to enable our clients to bring superior best-in-class diagnostic products to market faster.”
About Aalto Bio Reagents
Founded in 1978, Aalto Bio Reagents is a leading provider of raw materials to the in-vitro diagnostics industry and to research laboratories globally. We serve the largest multinational companies in our industry with a broad range of purified human proteins; monoclonal and polyclonal antibodies; fungal, parasitic, bacterial and viral antigens; and disease state plasma for in-vitro diagnostic application.
Since the company's inception we have built strong working relationships with our clients who trust us to provide them with the highest quality raw materials to meet the exacting standards of their own product development requirements. Headquartered in Dublin, Ireland, the company is rapidly expanding both its product portfolio and customer base.
For further information please visit http://www.aaltobioreagents.com
Contact: Sarah McElroy Tel: +353-1-4900685